ALTA3263 is an oral KRAS-selective inhibitor specifically designed to potently inhibit the KRAS “ON” (active) state of greater than 90% of all KRAS mutations and to provide complete target ...

The third drug, BBO-11818, is a pan-KRAS inhibitor targeting mutant versions KRAS proteins in both the “on” and “off” states. BridgeBio Oncology says this molecule is designed to offer ...

(A) Percentage of pancreatic cancers with currently targetable variants. (B) Percentage of pancreatic cancers with potentially targetable KRAS variants. Pancreatic cancer has recently gone from being ...

Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS ...

Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001Erasca will also present ...

Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025Ongoing Phase 3 ...

The firm's next-generation sequencing-based test detects single nucleotide variants, insertions, and deletions in 22 genes.

ALTA3263 is a potential best-in-class KRAS-selective small molecule inhibitor that potently targets >90% of KRAS mutations ALTA3263 is designed for complete KRAS target coverage, which will be ...